Show simple item record

dc.contributor.authorMichelson, Alan D.
dc.contributor.authorFurman, Mark I.
dc.date2022-08-11T08:10:10.000
dc.date.accessioned2022-08-23T16:58:18Z
dc.date.available2022-08-23T16:58:18Z
dc.date.issued1999-09-01
dc.date.submitted2012-04-25
dc.identifier.citationCurr Opin Hematol. 1999 Sep;6(5):342-8.
dc.identifier.issn1065-6251 (Linking)
dc.identifier.pmid10468151
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43339
dc.description.abstractWhole blood flow cytometry is a powerful new laboratory technique for assessment of platelet activation and function. Flow cytometry can be used to measure platelet hyperreactivity, circulating activated platelets, leukocyte-platelet aggregates, and procoagulant platelet-derived microparticles in a number of clinical settings, including acute coronary syndromes, angioplasty, cardiopulmonary bypass, acute cerebrovascular ischemia, peripheral vascular disease, diabetes mellitus, preeclampsia, and Alzheimer's disease. Clinical applications of whole blood flow cytometric assays of platelet function in these diseases may include identification of patients who would benefit from additional antiplatelet therapy and prediction of ischemic events. Circulating monocyte-platelet aggregates appear to be a more sensitive marker of in vivo platelet activation than circulating P-selectin-positive platelets. Flow cytometry can also be used in the following clinical settings: monitoring of glycoprotein IIb-IIIa antagonist therapy, diagnosis of inherited deficiencies of platelet surface glycoproteins, diagnosis of storage pool disease, diagnosis of heparin-induced thrombocytopenia, and measurement of the rate of thrombopoiesis.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10468151&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00062752-199909000-00012&LSLINK=80&D=ovft
dc.subjectBiological Markers
dc.subjectCerebrovascular Disorders
dc.subjectCoronary Disease
dc.subjectFlow Cytometry
dc.subjectHumans
dc.subjectPlatelet Activation
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectPlatelet Glycoprotein GPIIb-IIIa Complex
dc.subjectHematology
dc.subjectOncology
dc.subjectPediatrics
dc.titleLaboratory markers of platelet activation and their clinical significance
dc.typeJournal Article
dc.source.journaltitleCurrent opinion in hematology
dc.source.volume6
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_hematology/18
dc.identifier.contextkey2796505
html.description.abstract<p>Whole blood flow cytometry is a powerful new laboratory technique for assessment of platelet activation and function. Flow cytometry can be used to measure platelet hyperreactivity, circulating activated platelets, leukocyte-platelet aggregates, and procoagulant platelet-derived microparticles in a number of clinical settings, including acute coronary syndromes, angioplasty, cardiopulmonary bypass, acute cerebrovascular ischemia, peripheral vascular disease, diabetes mellitus, preeclampsia, and Alzheimer's disease. Clinical applications of whole blood flow cytometric assays of platelet function in these diseases may include identification of patients who would benefit from additional antiplatelet therapy and prediction of ischemic events. Circulating monocyte-platelet aggregates appear to be a more sensitive marker of in vivo platelet activation than circulating P-selectin-positive platelets. Flow cytometry can also be used in the following clinical settings: monitoring of glycoprotein IIb-IIIa antagonist therapy, diagnosis of inherited deficiencies of platelet surface glycoproteins, diagnosis of storage pool disease, diagnosis of heparin-induced thrombocytopenia, and measurement of the rate of thrombopoiesis.</p>
dc.identifier.submissionpathpeds_hematology/18
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages342-8


This item appears in the following Collection(s)

Show simple item record